Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Abstract PD17-01: Genomic analysis of circulating tumor DNA (ctDNA) from patients with HR+, HER2-mutant metastatic breast cancer (MBC) enrolled in SUMMIT: mechanisms of acquired resistance to neratinib + fulvestrant + trastuzumab (N+F+T)

Cynthia Ma, James Waisman, Adam M. Brufsky, Eddy S. Yang, Hans Wildiers, John P. Crown, Sarina A. Piha-Paul, Jennifer M. Suga, José Ángel García-Sáenz, Valentina Gambardella, Angel Guerrero, Salomon Stemmer, Ron Bose, Tonya Novara-Demgen, Daniel DiPrimeo, Lisa D. Eli, Komal Jhaveri

Cancer Res (2023) 83 (5_Supplement): PD17-01.

https://doi.org/10.1158/1538-7445.SABCS22-PD17-01

Published: 01 March 2023

View articletitled, Abstract PD17-01: Genomic analysis of circulating tumor DNA (ctDNA) from patients with HR+, HER2-mutant metastatic breast cancer (MBC) enrolled in SUMMIT: mechanisms of acquired resistance to neratinib + fulvestrant + trastuzumab (N+F+T)

Journal Articles

Abstract CT110: Olaparib (O) in patients (pts) with solid tumors with ATM mutation or deletion: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study

Cancer Res (2022) 82 (12_Supplement): CT110.

https://doi.org/10.1158/1538-7445.AM2022-CT110

Published: 15 June 2022

View articletitled, Abstract CT110: Olaparib (O) in patients (pts) with solid tumors with ATM mutation or deletion: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study

Journal Articles

Abstract GS4-10: Neratinib + fulvestrant + trastuzumab for hormone receptor-positive, HER2-mutant metastatic breast cancer and neratinib + trastuzumab for triple-negative disease: Latest updates from the SUMMIT trial

Komal Jhaveri, Haeseong Park, James Waisman, Jonathan W Goldman, Angel Guerrero-Zotano, Valentina Boni, Barbara Haley, Ingrid A Mayer, Adam Brufsky, Eddy S Yang, José A García-Sáenz, François-Clement Bidard, John Crown, Bo Zhang, Aimee Frazier, Irmina Diala, Lisa D Eli, Brian Barnett, Hans Wildiers

Cancer Res (2022) 82 (4_Supplement): GS4-10.

https://doi.org/10.1158/1538-7445.SABCS21-GS4-10

Published: 15 February 2022

View articletitled, Abstract GS4-10: Neratinib + fulvestrant + trastuzumab for hormone receptor-positive, HER2-mutant metastatic breast cancer and neratinib + trastuzumab for triple-negative disease: Latest updates from the SUMMIT trial

Journal Articles

Abstract PS10-30: An open label, pilot study of veliparib and lapatinib in patients with metastatic, triple negative breast cancer

Erica M Stringer-Reasor, Jori E May, Eva Olariu, Valeria Caterinicchia, Yufeng Li, Deborah Della Manna, Gabrielle B Rocque, Christos Vaklavas, Carla I Falkson, Lisle M Nabell, Edward P Acosta, Andres Forero-Torres, Eddy S Yang

Cancer Res (2021) 81 (4_Supplement): PS10-30.

https://doi.org/10.1158/1538-7445.SABCS20-PS10-30

Published: 15 February 2021

View articletitled, Abstract PS10-30: An open label, pilot study of veliparib and lapatinib in patients with metastatic, triple negative breast cancer

Journal Articles

Abstract 3920: Differential effects of Jumonji family demethylase and EZH2 H3K27 methyltransferase inhibition on radiation sensitivity of H3K27M mutant DIPG

Anatoly Y. Nikolaev, John B. Fiveash, Eddy S. Yang

Cancer Res (2019) 79 (13_Supplement): 3920.

https://doi.org/10.1158/1538-7445.AM2019-3920

Published: 01 July 2019

View articletitled, Abstract 3920: Differential effects of Jumonji family demethylase and EZH2 H3K27 methyltransferase inhibition on radiation sensitivity of H3K27M mutant DIPG

Journal Articles

Abstract CT139: NCI Molecular Analysis for Therapy Choice (NCI-MATCH EAY131) arm B: Phase II study of afatinib in patients (pts) with HER2 (ERBB2) activating mutations

Cancer Res (2019) 79 (13_Supplement): CT139.

https://doi.org/10.1158/1538-7445.AM2019-CT139

Published: 01 July 2019

View articletitled, Abstract CT139: NCI Molecular Analysis for Therapy Choice (NCI-MATCH EAY131) arm B: Phase II study of afatinib in patients (pts) with HER2 (ERBB2) activating mutations

Journal Articles

Abstract 1293: JQ1 sensitivity of patient-derived xenograft models of cholangiocarcinoma

Aubrey L. Miller, Patrick L. Garcia, Tracy L. Gamblin, Leona N. Council, Xiangqin Cui, James E. Bradner, Eddy S. Yang, Karina J. Yoon

Cancer Res (2016) 76 (14_Supplement): 1293.

https://doi.org/10.1158/1538-7445.AM2016-1293

Published: 15 July 2016

View articletitled, Abstract 1293: JQ1 sensitivity of patient-derived xenograft models of cholangiocarcinoma

Journal Articles

Abstract A1-63: Characterizing the DNA damage repair defect in HPV-positive oropharyngeal squamous cell carcinoma

Alice N. Weaver, Tiffiny S. Cooper, Hoa Q. Trummell, James A. Bonner, Eben L. Rosenthal, Eddy S. Yang

Cancer Res (2015) 75 (22_Supplement_1): A1-63.

https://doi.org/10.1158/1538-7445.TRANSCAGEN-A1-63

Published: 15 November 2015

View articletitled, Abstract A1-63: Characterizing the DNA damage repair defect in HPV-positive oropharyngeal squamous cell carcinoma

Journal Articles

Abstract 1779: Bromodomain inhibitor JQ1 inhibits cholangiocarcinoma tumor growth in patient-derived xenograft models

Patrick L. Garcia, Aubrey L. Miller, Kelly Kreitzburg, Tracy L. Gamblin, Leona N. Council, John D. Christein, Pablo Arnoletti, Marty Heslin, Sushanth Reddy, Joseph H. Richardson, Eddy S. Yang, Jun Qi, James E. Bradner, Karina J. Yoon

Cancer Res (2015) 75 (15_Supplement): 1779.

https://doi.org/10.1158/1538-7445.AM2015-1779

Published: 01 August 2015

View articletitled, Abstract 1779: Bromodomain inhibitor JQ1 inhibits cholangiocarcinoma tumor growth in patient-derived xenograft models

Journal Articles

Abstract 5469: Trastuzumab resistant HER2+ breast cancer cells retain sensitivity to poly (ADP-ribose) polymerase (PARP) inhibition

Monica E. Wielgos, Tiffiny Cooper, Andres Forero, James A. Bonner, Francisco J. Esteva, C K. Osborne, Rachel Schiff, Albert F. LoBuglio, Eddy S. Yang

Cancer Res (2014) 74 (19_Supplement): 5469.

https://doi.org/10.1158/1538-7445.AM2014-5469

Published: 01 October 2014

View articletitled, Abstract 5469: Trastuzumab resistant HER2+ breast cancer cells retain sensitivity to poly (ADP-ribose) polymerase (PARP) inhibition

Journal Articles

Abstract 635: PARP inhibition in HPV positive head and neck cancers.

Tiffiny Cooper, Marcela Rodriguez, Hoa Q. Trummell, Alice Weaver, James A. Bonner, Eddy S. Yang

Cancer Res (2013) 73 (8_Supplement): 635.

https://doi.org/10.1158/1538-7445.AM2013-635

Published: 15 April 2013

View articletitled, Abstract 635: PARP inhibition in HPV positive head and neck cancers.

Journal Articles

Abstract 5475: Endoglin (CD105) is a target for ovarian cancer cell-specific therapy through induction of DNA damage.

Angela J. Ziebarth, Somaria Nowsheen, Adam D. Steg, Monjri M. Shah, Ashwini A. Katre, Zachary C. Dobbin, Anil K. Sood, Michael G. Conner, Eddy S. Yang, Charles N. Landen

Cancer Res (2013) 73 (8_Supplement): 5475.

https://doi.org/10.1158/1538-7445.AM2013-5475

Published: 15 April 2013

View articletitled, Abstract 5475: Endoglin (CD105) is a target for ovarian cancer cell-specific therapy through induction of DNA damage.

Journal Articles

Targeting BRCA1 Localization to Augment Breast Tumor Sensitivity to Poly(ADP-Ribose) Polymerase Inhibition

Eddy S. Yang, Somaira Nowsheen, Mohammad A. Rahman, Rebecca S. Cook, Fen Xia

Cancer Res (2012) 72 (21): 5547–5555.

https://doi.org/10.1158/0008-5472.CAN-12-0934

Published: 31 October 2012

View articletitled, Targeting BRCA1 Localization to Augment Breast Tumor Sensitivity to Poly(ADP-Ribose) Polymerase Inhibition

Includes: Supplementary data

Journal Articles

HER2 Overexpression Renders Human Breast Cancers Sensitive to PARP Inhibition Independently of Any Defect in Homologous Recombination DNA Repair

Somaira Nowsheen, Tiffiny Cooper, James A. Bonner, Albert F. LoBuglio, Eddy S. Yang

Cancer Res (2012) 72 (18): 4796–4806.

https://doi.org/10.1158/0008-5472.CAN-12-1287

Published: 16 September 2012

View articletitled, HER2 Overexpression Renders Human Breast Cancers Sensitive to PARP Inhibition Independently of Any Defect in Homologous Recombination DNA Repair

Includes: Supplementary data

Journal Articles

Abstract 4684: Synthetic lethal interaction between EGFR and PARP inhibition

Alexander Whitley, Somaira Nowsheen, Tiffiny Cooper, Albert LoBuglio, James Bonner, Eddy S. Yang

Cancer Res (2012) 72 (8_Supplement): 4684.

https://doi.org/10.1158/1538-7445.AM2012-4684

Published: 15 April 2012

View articletitled, Abstract 4684: Synthetic lethal interaction between EGFR and PARP inhibition

Journal Articles

p53-Dependent BRCA1 Nuclear Export Controls Cellular Susceptibility to DNA Damage

Juhong Jiang, Eddy S. Yang, Guochun Jiang, Somaira Nowsheen, Hong Wang, Tong Wang, Yihan Wang, Dean Billheimer, A. Bapsi Chakravarthy, Melissa Brown, Bruce Haffty, Fen Xia

Cancer Res (2011) 71 (16): 5546–5557.

https://doi.org/10.1158/0008-5472.CAN-10-3423

Published: 11 August 2011

View articletitled, p53-Dependent BRCA1 Nuclear Export Controls Cellular Susceptibility to DNA Damage

Includes: Supplementary data

Journal Articles

Abstract 5496: Cetuximab induces synthetic lethality with the poly (ADP-Ribose) polymerase (PARP) inhibitor ABT-888 in head and neck cancer

Alexander C. Whitley, Somaira Nowsheen, Hoa Trummell, Albert LoBuglio, James A. Bonner, Eddy S. Yang

Cancer Res (2011) 71 (8_Supplement): 5496.

https://doi.org/10.1158/1538-7445.AM2011-5496

Published: 15 April 2011

View articletitled, Abstract 5496: Cetuximab induces synthetic lethality with the poly (ADP-Ribose) polymerase (PARP) inhibitor ABT-888 in head and neck cancer

Journal Articles

DNA Damage–Induced Cytotoxicity Is Dissociated from BRCA1's DNA Repair Function but Is Dependent on Its Cytosolic Accumulation

Hong Wang, Eddy S. Yang, Juhong Jiang, Somaira Nowsheen, Fen Xia

Cancer Res (2010) 70 (15): 6258–6267.

https://doi.org/10.1158/0008-5472.CAN-09-4713

Published: 28 July 2010

View articletitled, DNA Damage–Induced Cytotoxicity Is Dissociated from BRCA1's DNA Repair Function but Is Dependent on Its Cytosolic Accumulation

Journal Articles

Erlotinib Attenuates Homologous Recombinational Repair of Chromosomal Breaks in Human Breast Cancer Cells

Liping Li, Hong Wang, Eddy S. Yang, Carlos L. Arteaga, Fen Xia

Cancer Res (2008) 68 (22): 9141–9146.

https://doi.org/10.1158/0008-5472.CAN-08-1127

Published: 14 November 2008

View articletitled, Erlotinib Attenuates Homologous Recombinational Repair of Chromosomal Breaks in Human Breast Cancer Cells

Includes: Supplementary data

Journal Articles

Abnormal Regulation of DNA Methyltransferase Expression during Colorectal Carcinogenesis

Angelo M. De Marzo, Valerie L. Marchi, Eddy S. Yang, Ravi Veeraswamy, Xiaohui Lin, William G. Nelson

Cancer Res (1999) 59 (16): 3855–3860.

Published: 15 August 1999

View articletitled, Abnormal Regulation of DNA Methyltransferase Expression during Colorectal Carcinogenesis

Update search

NARROW

Format

Subjects

Journal

Article Type

Issue Section

Date

Availability

Abstract PD17-01: Genomic analysis of circulating tumor DNA (ctDNA) from patients with HR+, HER2-mutant metastatic breast cancer (MBC) enrolled in SUMMIT: mechanisms of acquired resistance to neratinib + fulvestrant + trastuzumab (N+F+T)

Abstract CT110: Olaparib (O) in patients (pts) with solid tumors with ATM mutation or deletion: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study

Abstract GS4-10: Neratinib + fulvestrant + trastuzumab for hormone receptor-positive, HER2-mutant metastatic breast cancer and neratinib + trastuzumab for triple-negative disease: Latest updates from the SUMMIT trial

Abstract PS10-30: An open label, pilot study of veliparib and lapatinib in patients with metastatic, triple negative breast cancer

Abstract 3920: Differential effects of Jumonji family demethylase and EZH2 H3K27 methyltransferase inhibition on radiation sensitivity of H3K27M mutant DIPG

Abstract CT139: NCI Molecular Analysis for Therapy Choice (NCI-MATCH EAY131) arm B: Phase II study of afatinib in patients (pts) with HER2 (ERBB2) activating mutations

Abstract 1293: JQ1 sensitivity of patient-derived xenograft models of cholangiocarcinoma

Abstract A1-63: Characterizing the DNA damage repair defect in HPV-positive oropharyngeal squamous cell carcinoma

Abstract 1779: Bromodomain inhibitor JQ1 inhibits cholangiocarcinoma tumor growth in patient-derived xenograft models

Abstract 5469: Trastuzumab resistant HER2+ breast cancer cells retain sensitivity to poly (ADP-ribose) polymerase (PARP) inhibition

Abstract 635: PARP inhibition in HPV positive head and neck cancers.

Abstract 5475: Endoglin (CD105) is a target for ovarian cancer cell-specific therapy through induction of DNA damage.

Targeting BRCA1 Localization to Augment Breast Tumor Sensitivity to Poly(ADP-Ribose) Polymerase Inhibition

HER2 Overexpression Renders Human Breast Cancers Sensitive to PARP Inhibition Independently of Any Defect in Homologous Recombination DNA Repair

Abstract 4684: Synthetic lethal interaction between EGFR and PARP inhibition

p53-Dependent BRCA1 Nuclear Export Controls Cellular Susceptibility to DNA Damage

Abstract 5496: Cetuximab induces synthetic lethality with the poly (ADP-Ribose) polymerase (PARP) inhibitor ABT-888 in head and neck cancer

DNA Damage–Induced Cytotoxicity Is Dissociated from BRCA1's DNA Repair Function but Is Dependent on Its Cytosolic Accumulation

Erlotinib Attenuates Homologous Recombinational Repair of Chromosomal Breaks in Human Breast Cancer Cells

Abnormal Regulation of DNA Methyltransferase Expression during Colorectal Carcinogenesis

Email alerts

AACR Journals

Update search

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only